Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Neuraxis, Inc. (NRXS : AMEX)

• Company Description    NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis, Inc. is based in CARMEL, Ind. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $2.58 Daily Weekly Monthly 20 Day Moving Average: 122,755 shares Shares Outstanding: 7.22 (millions) Market Capitalization: $18.62 (millions) Beta: 3.09 52 Week High: $3.99 52 Week Low: $1.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.15% -5.54% 12 Week 44.13% 23.11% Year To Date 9.79% 2.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11611 N. Meridian Street Suite 330 - Carmel,IN 46032 USA ph: 812-689-0791 fax: - ir@neuraxis.com https://neuraxis.com

• General Corporate Information    Officers Brian Carrico - President; Chief Executive Officer; and Director Bradley Mitch Watkins - Director and Chairman of the Board Timothy Henrichs - Chief Financial Officer Adrian Miranda - Chief Medical Officer; Senior Vice President of Sc Christopher Robin Brown - Director Peer Information Neuraxis, Inc. (HLIS) Neuraxis, Inc. (AZTA) Neuraxis, Inc. (APYI) Neuraxis, Inc. (RNVA) Neuraxis, Inc. (HMSY) Neuraxis, Inc. (LRSI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MEDICAL INFO SYS Sector: Medical CUSIP: 64134X201 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 7.22 Most Recent Split Date: (:1) Beta: 3.09 Market Capitalization: $18.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 73.38 Price/Cash Flow: - Price / Sales: 6.34 EPS Growth vs. Year Ago Period: 3.12% vs. Previous Quarter: -47.62% Sales Growth vs. Year Ago Period: 38.49% vs. Previous Quarter: 17.74% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -297.92 12/31/24 - -347.76 Current Ratio 06/30/25 - - 03/31/25 - 1.21 12/31/24 - 1.75 Quick Ratio 06/30/25 - - 03/31/25 - 1.19 12/31/24 - 1.74 Operating Margin 06/30/25 - - 03/31/25 - -293.36 12/31/24 - -306.74 Net Margin 06/30/25 - - 03/31/25 - -293.36 12/31/24 - -306.74 Pre-Tax Margin 06/30/25 - - 03/31/25 - -286.10 12/31/24 - -306.85 Book Value 06/30/25 - - 03/31/25 - 0.04 12/31/24 - 0.30 Inventory Turnover 06/30/25 - - 03/31/25 - 11.61 12/31/24 - 11.16 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©